Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MMRVNS

Phase 3Biologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

MeaslesRecruiting

MeaslesPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Measles

NCT07406360

Clinical

Trials by Indication[1]

Measles1 trial

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

Recruiting· GSK logo

GSK·Phase 3·NCT07406360·1,209 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MMRVNS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MMRVNS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MMRVNS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK

Related News